<https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> <http://purl.org/pav/retrievedFrom> <https://www.guidetopharmacology.org/coronavirus.jsp> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> <http://purl.org/pav/retrievedOn> "2020-07-24T04:10:11"^^<http://www.w3.org/2001/XMLSchema#dateTime> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/Protein> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/Protein/0.11-RELEASE/" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614> <https://schema.org/description> "Anchoring or binding site on host cells that is exploited by some betacoronaviruses for viral entry. Engaged by SARS-CoV-2 spike protein as the first step towards infection of host cells." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614> <https://schema.org/identifier> "1614" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614> <https://schema.org/name> "ACE2" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3127> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/Protein> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3127> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/Protein/0.11-RELEASE/" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3127> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3127> <https://schema.org/description> "SARS-CoV-2 may utilise CD147 as an additional entry receptor to infect host cells. The anti-CD147 mAb, meplazumab, can block the interaction between CD147 and SARS-CoV-2 spike protein (bioRxiv preprint article, Wang et al. (2020) https://doi.org/10.1101/2020.03.14.988345). Already under clinical evaluation in NCT04275245." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3127> <https://schema.org/identifier> "3127" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3127> <https://schema.org/name> "CD147 (basign, HGNC:1116)" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3127> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3127> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/Protein> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/Protein/0.11-RELEASE/" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111> <https://schema.org/description> "Inhibitors of this viral protease have the potential to block cleavage of nascent viral proteins as they are synthesised in host cells." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111> <https://schema.org/identifier> "3111" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111> <https://schema.org/name> "SARS-CoV-2 main protease" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/Protein> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/Protein/0.11-RELEASE/" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421> <https://schema.org/description> "Involved in the activation of viral glycoproteins/viral entry across a range of viruses, including SARS-CoV-2. SARS-CoV-2 entry is partially blocked in vitro by the protease inhibitor camostat." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421> <https://schema.org/identifier> "2421" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421> <https://schema.org/name> "TMPRSS2" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198#> <https://schema.org/description> "An existing antimalarial drug, with in vitro activity against SARS-CoV (PMID: 16640347), that is being repositioned to treat COVID-19. Preliminary evidence from a small cohort of COVID-19 patients suggests that a combination of hydroxychloroquine + the antibiotic azithromycin significantly reduces detectable viral RNA (compared to hydroxychloroquine alone or placebo; In press 17 March 2020 IJAA DOI : 10.1016/j.ijantimicag.2020.105949). However, extreme caution must be taken when considering using hydroxychloroquine as it has severe cardiac adverse effects, and in addition its distribution to lung tissue is unknown. Read Derek Lowe's 'In the Pipeline' blog https://blogs.sciencemag.org/pipeline/archives/2020/04/16/more-small-molecule-clinical-data-against-covid-19-as-of-april-16 which provides a systematic and considered anaylsis of the (lack of) potential for hydroxychloroquine/chloroquine for COVID-19." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198#> <https://schema.org/identifier> "7198" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198#> <https://schema.org/name> "hydroxychloroquine" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747#> <https://schema.org/description> "Anti-SARS-CoV-2 activity in vitro https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747#> <https://schema.org/identifier> "10747" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747#> <https://schema.org/name> "ONO-5334" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804#> <https://schema.org/description> "Anti-HIV combination that could be repurposed for COVID-19. This is a clinically used, orally administered anti-HIV combination drug therapy, so safety has been established.Two separate clinical trials have reported no clinical efficacy for this medication in severe COVID-19; No significant benefit, compared to standard therapy, was observed in patients with severe COVID-19 (results reported for Chinese trial ChiCTR2000029308 http://www.chictr.org.cn/showprojen.aspx?proj=48684 in NEJM 18/03/2020 PMID: 32187464 https://pubmed.ncbi.nlm.nih.gov/32187464). The UK RECOVERY trial also reported lack of efficacy for this combo in late June 2020 https://bit.ly/2YMwHGH. The RECOVERY team noted that it was impossible to study a large number of patients on invasive mechanical ventilation because the oral mode of delivery was incompatible with invasive ventilation." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804#> <https://schema.org/identifier> "8804" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804#> <https://schema.org/name> "ritonavir" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716#> <https://schema.org/description> "PRD_002214 is a viral main protease inhibitor. It has been crystalised in complex with the SARS-CoV-2 Mpro (RCSB Protein Databank ID 6LU7)." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716#> <https://schema.org/identifier> "10716" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716#> <https://schema.org/name> "PRD_002214" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737#> <https://schema.org/description> "A novel, orally bioavailable RNA-dependent RNA polymerase inhibitor, that targets replication of RNA viruses PMID: 32253226, developed by Ridgeback Biotherapeutics. Being advanced to clinical trial in the UK and US (Phase 1 in healthy volunteers), and 2x Phase 2 in recently diagnosed COVID-19 patients in the US." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737#> <https://schema.org/identifier> "10737" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737#> <https://schema.org/name> "EIDD-2801" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758#> <https://schema.org/description> "An anti-PD-1 checkpoint inhibitor approved in China as an immuno-oncology biologic. Being compared to thymosin for the prevention of sepsis in COVID-19 patients." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758#> <https://schema.org/identifier> "9758" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758#> <https://schema.org/name> "camrelizumab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771#> <https://schema.org/description> "Approved anti-VEGFA mAb. Phase 2/3 NCT04275414 aims to determine if suppression of vascular permeability will reduce pulmonary edema in patients with severe/critical COVID-19." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771#> <https://schema.org/identifier> "6771" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771#> <https://schema.org/name> "bevacizumab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10752#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10752#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10752#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10752#> <https://schema.org/description> "A clinical stage anti-CCR5 mAb with immunomodulatory potential. Being evaluated in Ph2 clinical trials in COVID-19 patients as a strategy to reduce cytokine storm and related pathophysiological sequelae." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10752#> <https://schema.org/identifier> "10752" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10752#> <https://schema.org/name> "leronlimab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10752#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10752> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732#> <https://schema.org/description> "A direct serine protease factor Xa inhibitor, and failed anticoagulant candidate drug; predicted binding energy when virtually docked with TMPRSS2; associated with bleeding-related adverse effects in clinical study." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732#> <https://schema.org/identifier> "10732" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732#> <https://schema.org/name> "otamixaban" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891#> <https://schema.org/description> "A VIP analogue, VPAC1 receptor agonist that is already in clinical use. Preclinical and clinical experience shows that aviptadil restores function in pulmonary hypertension, ARDS, and acute lung injury (ALI), reduces IL-6 and TNFalpha production, and protects against pulmonary edema. This combination of benefits has led to aviptadil being investigated as a treatment option for ARDS in COVID-19 patients (NCT04311697)." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891#> <https://schema.org/identifier> "10891" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891#> <https://schema.org/name> "aviptadil" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10891> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004#> <https://schema.org/description> "The case for re-purposing approved anti-TNF biologic therapies as a means to combat cytokine storm and inflammation in COVID-19 patients is presented in PMID: 32278362." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004#> <https://schema.org/identifier> "5004" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004#> <https://schema.org/name> "infliximab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327#> <https://schema.org/description> "Thalidomide + low-dose glucocorticoid, and thalidomide + celecoxib are two approaches being evaluated for clinical efficacy in patients with severe COVID-19. These combine the immunosuppressive action of thalidomide with the anti-inflammatory actions of glucocorticoids and COX inhibition respectively. See NCT04273529 and NCT04273581 as examples." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327#> <https://schema.org/identifier> "7327" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327#> <https://schema.org/name> "thalidomide" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404#> <https://schema.org/description> "Zilucoplan is an investigational complement pathway inhibitor with anti-inflammatory potential. It acts as a functional inhibitor of membrane attack complex (MAC) formation. It is being progressed to clinical trial in COVID-19 patients as part of the UK's ACCORD initiative https://bit.ly/2ZXjXOw, to determine if it has efficacy in reducing the hyper-inflammatory response that is a component of severe COVID-19." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404#> <https://schema.org/identifier> "10404" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404#> <https://schema.org/name> "zilucoplan" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11026#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11026#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11026#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11026#> <https://schema.org/description> "An anti-CD147 (basigin, BSG) mAb. SARS-CoV-2 may utilise CD147 as an additional entry receptor to infect host cells. Meplazumab can block the interaction between CD147 and SARS-CoV-2 spike protein (bioRxiv preprint article, Wang et al. (2020) https://doi.org/10.1101/2020.03.14.988345). Already under clinical evaluation in NCT04275245." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11026#> <https://schema.org/identifier> "11026" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11026#> <https://schema.org/name> "meplazumab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11026#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11026> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967#> <https://schema.org/description> "Recombinant formulations of IFN-beta are used to treat multiple sclerosis (MS), so safety has been established. IFN-beta is a key modulator of immune defence against viruses. The coronavirus seems to suppress production of types I and III IFNs (IFN-beta is a type I IFN) as part of its strategy to evade immune detection and destruction (Blanco-Melo et al., 2020 In press. DOI: 10.1016/j.cell.2020.04.026). Administering exogenous IFN-beta directly to the lungs is predicted to re-engage the anti-viral immune response to SARS-CoV-2. One such formulation is SNG001 (Synairgen Research) that can be delivered directly to the lungs via a nebuliser. SNG001 was initially designed to treat viral infection-related exacerbations in COPD patients (currently in Phase 2), but has been rapidly re-deployed for coronavirus infection." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967#> <https://schema.org/identifier> "4967" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967#> <https://schema.org/name> "IFN-&beta;" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972#> <https://schema.org/description> "An approved IL-1 pathway blocking peptide, that has anti-inflammatory action. This Comment in The Lancet Rheumatology discusses factors to be considered when planning anakinra trials for COVID-19 hyperinflammatory response https://bit.ly/2yu89Ig." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972#> <https://schema.org/identifier> "6972" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972#> <https://schema.org/name> "anakinra" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407#> <https://schema.org/description> "An approved S1P1 receptor inhibitor that has immunomodulatory/immunosuppresant actions. This could be applied to the management of the inflammatory aspects of COVID-19. Clinical efficacy will be evaluated in Phase 2 study NCT04280588." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407#> <https://schema.org/identifier> "2407" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407#> <https://schema.org/name> "fingolimod" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715#> <https://schema.org/description> "Nucleotide analogue antiviral with broad-spectrum activity against RNA viruses. Used on compassionate grounds to treat the first SARS-CoV-2 +ve patient in the US. Phase 3 trial NCT04292899 to be carried out in patients with severe COVID-19 is in preparation. Derek Lowe provides a systematic and considered anaylsis of the potential for remdesivir in COVID-19 via his 'In the Pipeline' blog ,https://blogs.sciencemag.org/pipeline/archives/2020/04/16/more-small-molecule-clinical-data-against-covid-19-as-of-april-16. Results from China in late April 2020 detected no significant clinical efficacy, but the investigators noted that remdesivir reduced time to clinical improvement (published in The Lancet DOI:https://doi.org/10.1016/S0140-6736(20)31022-9). This effect of accelerating recovery appears to have been replicated in a NIH-sponsored trial, but results have not been formally published. Effectively inhibits a clinical isolate of SARS-CoV-2 in vitro PMID: 32020029." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715#> <https://schema.org/identifier> "10715" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715#> <https://schema.org/name> "remdesivir" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706#> <https://schema.org/description> "This is a compound that inhibits the SARS-CoV main protease (Mpro), and has potential to inhibit the SARS-CoV-2 Mpro, structural similarities between the 2 enzymes permitting. X-ray structure of 11r bound to SARS-CoV Mpro is deposited with the RSCB Protein Databank (ID 5N5O)." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706#> <https://schema.org/identifier> "10706" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706#> <https://schema.org/name> "compound 15 [PMID: 32045236]" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768#> <https://schema.org/description> "A widely used and low-cost anti-inflammatory corticosteroid drug. On June 16th 2020, it was reported that results from the UK RECOVERY trial have shown a clear survival benefit of low-dose dexamethasone in COVID-19 patients with severe respiratory complications. It cut the risk of death by a third for patients on ventilators and by 20% for those on oxygen. Dexamethasone does not appear to help patients with milder symptoms of coronavirus. Results have now been submitted to the medRxiv preprint server: Horby et al. (2020) Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report (https://doi.org/10.1101/2020.06.22.20137273). In the UK, dexamethasone was authorised in mid-June 2020 for use within the NHS, as the first coronavirus treatment proven to reduce mortality https://bit.ly/2VPWKuY." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768#> <https://schema.org/identifier> "2768" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768#> <https://schema.org/name> "dexamethasone" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902#> <https://schema.org/description> "TRV027 was a clinical candidate for heart failure that was studied through to Phase 2b, so has been tested in humans. A clinical trial (NCT04419610; Imperial College London) has been designed to establish if antagonising the renin-angiotensin system with TRV027 has efficacy to combat acute lung injury and ARDS in COVID-19 patients. If successful this would offer an additional option to anti-virals and anti-inflammatory therapies to address the umet clinical need for treating this multi-system, multi-organ disease." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902#> <https://schema.org/identifier> "6902" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902#> <https://schema.org/name> "TRV027" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262#> <https://schema.org/description> "A protease inhibitor approved in Japan. Now being evaluated in combination with favipiravir in a RCT in patients with COVID-19 pneumonia (clinical trial number jRCTs031200026). Nafamostat is being proposed to reduce SARS-CoV-2 entry by inhibiting the host protease TMPRSS2 [PMID:27550352], and to additionally counteract COVID-19-associated thrombosis via its established anticoagulant activity." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262#> <https://schema.org/identifier> "4262" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262#> <https://schema.org/name> "nafamostat" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535#> <https://schema.org/description> "Antiretroviral, protease inhibitor. Cobicistat increases its bioavailability and half life. Phase 3 NCT04252274 for COVID-19." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535#> <https://schema.org/identifier> "7535" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535#> <https://schema.org/name> "cobicistat" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367#> <https://schema.org/description> "Colchicine is an approved drug, so safety in humans is established. It is used to treat gout and autoinflammatory diseases. Activated neutrophils can impede clot resolution through production of the endogenous antimicrobial peptide α-defensin-1, which acts to stabilise fibrin formation and reduce fibrinolysis. Colchicine-induced neutrophil depletion inhibits this release of α-defensin-1 and reduces thrombus formation in experimental systems (PMID: 30705047). Based on these observations clochicine has been entered into clinical trials (https://bit.ly/3eBTB8G) that aim to evaluate its efficacy as a therapy to help treat, and/or prevent the development of, inflammation-driven severe clotting abnormalities that occur in COVID-19 patients." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367#> <https://schema.org/identifier> "2367" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367#> <https://schema.org/name> "colchicine" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792#> <https://schema.org/description> "Approved JAK1/2 inhibitor. AI predicts antiviral activity via inhibition of AAK1 which is an important regulator of clathrin-mediated endocytosis, so has potential to inhibit viral entry into host cells in addition to its potent anti-inflammatory efficacy." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792#> <https://schema.org/identifier> "7792" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792#> <https://schema.org/name> "baricitinib" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720#> <https://schema.org/description> "A more drug-like derivative of 11r (10706) that inhibits the SARS-CoV-2 main protease (Mpro) PMID: 32198291. Exhibits potential for direct delivery to the lungs via inhalation route." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720#> <https://schema.org/identifier> "10720" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720#> <https://schema.org/name> "compound 13b [PMID: 32198291]" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214#> <https://schema.org/description> "Heparin is being used in ICU settings (based on observational efficacy) to mitigate against COVID-19-associated thromboembolic events (heart attack, stroke, pulmonary embolism). It is being progressed to clinical trial in COVID-19 patients as part of the UK's ACCORD initiative https://bit.ly/2ZXjXOw. Experimental evidence suggests that heparin (and non-anticoagulant heparan sulfate) directly binds the coronavirus, so could potentially be administered as a decoy to neutralise the virus before it can infect healthy cells via ACE2 PMID: 32653452." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214#> <https://schema.org/identifier> "4214" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214#> <https://schema.org/name> "heparin" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469#> <https://schema.org/description> "Ciclesonide (an approved corticosteroid used to treat respiratory inflammation) can inhibit SARS-CoV-2 replication via inhibition of viral nsp15 (bioRxiv preprint article Matsuyama et al. (2020) https://doi.org/10.1101/2020.03.11.987016)." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469#> <https://schema.org/identifier> "7469" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469#> <https://schema.org/name> "ciclesonide" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688#> <https://schema.org/description> "An approved anti-inflammatory JAK1/2/TYK2 inhibitor. Under clinical evaluation for Covid-19 (in combination with mesenchymal stem cell infusion)." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688#> <https://schema.org/identifier> "5688" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688#> <https://schema.org/name> "ruxolitinib" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811#> <https://schema.org/description> "An approved anti-clotting agent. Given evidence of heparin as a potential attachment factor for the coronavirus, a trial to determine the efficacy of early treatment with enoxaparin in COVID-19 patients has been initiated in Italy (March 2020)." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811#> <https://schema.org/identifier> "6811" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811#> <https://schema.org/name> "enoxaparin" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884#> <https://schema.org/description> "Approved mAb that binds complement factor C5 and blocks membrane attack complex formation." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884#> <https://schema.org/identifier> "6884" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884#> <https://schema.org/name> "eculizumab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862#> <https://schema.org/description> "Developed as a cathepsin K inhibitor but has activity against cathepsin L that may provide potential to block SARS-Cov-2 entry into host cells." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862#> <https://schema.org/identifier> "7862" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862#> <https://schema.org/name> "relacatib" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881#> <https://schema.org/description> "Approved immunosuppressive anti-IL-6 receptor mAb. China's National Health Commission has authorised its use to treat patients with serious COVID-19-induced lung damage, and results have been posted on the preprint server of the Chinese Academy of Sciences. (ChinaXiv), http://www.chinaxiv.org/abs/202003.00026, DOI: 10.12074/202003.00026. Phase 2 trial TOCIVID-19 (NCT04317092) is underway in Italy." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881#> <https://schema.org/identifier> "6881" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881#> <https://schema.org/name> "tocilizumab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432#> <https://schema.org/description> "Serine protease inhibitor with activity against the host TMPRSS2 protease that is exploited by SARS-CoV-2 to mediate viral entry." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432#> <https://schema.org/identifier> "6432" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432#> <https://schema.org/name> "camostat" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912#> <https://schema.org/description> "Acalabrutinib is an approved BTK inhibitor that is used to treat B cell malignancies. It is being progressed to clinical trial in COVID-19 patients as part of the UK's ACCORD initiative https://bit.ly/2ZXjXOw. Preliminary data from off-label use in the US suggests that acalabrutinib therapy normalises markers of inflammation (CRP, IL-6) in patients with severe COVID-19, and that targeting host hyperinflammation via BTK inhibition is a rational therapeutic strategy can improve patient outcomes in this disease (https://pubmed.ncbi.nlm.nih.gov/32503877)." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912#> <https://schema.org/identifier> "8912" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912#> <https://schema.org/name> "acalabrutinib" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746#> <https://schema.org/description> "Anti-SARS-CoV-2 activity in vitro https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746#> <https://schema.org/identifier> "10746" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746#> <https://schema.org/name> "VBY-825" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999#> <https://schema.org/description> "Approved immunosuppressive anti-IL-6 receptor mAb. Four COVID-19 trials underway as of March 30 2020, including the French open-label CORIMUNO-SARI study NCT04324073. Results from an Italian clinical trial were published in July 2020, which concluded that whilst sarliumab accelerated recovery in a subset of patients showing minor lung consolidation at baseline, there was no overall mortality benefit detected in patients with severe COVID-19 compared to standard of care PMID: 32620597" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999#> <https://schema.org/identifier> "7999" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999#> <https://schema.org/name> "sarilumab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4860#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4860#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4860#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4860#> <https://schema.org/description> "The case for re-purposing approved anti-TNF biologic therapies as a means to combat cytokine storm and inflammation in COVID-19 patients is presented in PMID: 32278362." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4860#> <https://schema.org/identifier> "4860" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4860#> <https://schema.org/name> "adalimumab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4860#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4860> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687#> <https://schema.org/description> "Abelson kinase (Abl) inhibitors are reported to block Spike protein-induced SARS-CoV and MERS-CoV fusion in vitro PMID: 29557770, potentially by blocking Abl2 at the endosomal membrane PMID: 27466418. It will be informative to determine if this holds true for SARS-CoV-2, and whether re-purposing of imatinib and/or newer Abl kinase inhibitors (dasatinib; bosutinib) could be a viable strategy against COVID-19. Likely to be most effective during the early stage of infection." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687#> <https://schema.org/identifier> "5687" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687#> <https://schema.org/name> "imatinib" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412#> <https://schema.org/description> "AZD7986 inhibits activation of neutrophil elastase via direct inhibition of dipeptidyl peptidase 1, that is being investigated as a treament for neutrophilic lung inflammation. It has been shown to produce on-target effects in healthy trial volunteers (PMID: 29484635). Plans are underway to examine the potential of AZD7986 (now being progressed by Insmed as INS1007) to treat COVID-19-related acute respiratory distress syndrome (ARDS), in the UK STOP-COVID19 clinical trial. The INS1007 arm of the study aims to administer the drug to 150 COVID-19 patients (plus 150 in the placebo arm) across 10 UK hospitals." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412#> <https://schema.org/identifier> "9412" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412#> <https://schema.org/name> "brensocatib" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031#> <https://schema.org/description> "An approved immunosuppressive drug. Sirolimus inhibits MERS-CoV infection of human liver cells in vitro; may be applicable to SARS-CoV-2 infection." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031#> <https://schema.org/identifier> "6031" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031#> <https://schema.org/name> "sirolimus" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624#> <https://schema.org/description> "An anti-GM-CSF (CSF2) mAb currently in clinical trial for anti-inflammatory potential in the treatment of autoimmune inflammation and cancer. Has been repurposed for deranged inflammation in COVID-19 (Phase 2, NCT04351243)." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624#> <https://schema.org/identifier> "9624" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624#> <https://schema.org/name> "gimsilumab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295#> <https://schema.org/description> "An approved anti-IFNγ mAb, which could target elevated cytokine production during COVID-19 infection." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295#> <https://schema.org/identifier> "9295" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295#> <https://schema.org/name> "emapalumab" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745#> <https://schema.org/description> "Anti-SARS-CoV-2 activity in vitro https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745#> <https://schema.org/identifier> "10745" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745#> <https://schema.org/name> "MDL-28170" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9859#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9859#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9859#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9859#> <https://schema.org/description> "A clinical stage inhibitor of the type III phosphoinostol kinase, PIKfyve. Anti-SARS-CoV-2 activity in vitro https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9859#> <https://schema.org/identifier> "9859" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9859#> <https://schema.org/name> "apilimod" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9859#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9859> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535#> <https://schema.org/description> "Effectively inhibits a clinical isolate of SARS-CoV-2 in vitro PMID: 32020029." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535#> <https://schema.org/identifier> "5535" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535#> <https://schema.org/name> "chloroquine" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036#> <https://schema.org/description> "An approved drug that acts as a selective inhibitor of nuclear export (SINE). SINE compounds have been shown to disrupt the replication of multiple viruses in vitro and in vivo and to mediate anti-inflammatory and anti-viral effects in animal models. In respect of SARS-CoV-2, SINE compounds have been reported to exhibit potential to interfere with interactions between viral proteins and key host proteins [PMID:32353859]. Based on this in vitro observation, low-dose selinexor has been advanced to Phase 2 investigation in patients with severe COVID-19 (NCT04349098)." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036#> <https://schema.org/identifier> "10036" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036#> <https://schema.org/name> "selinexor" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692#> <https://schema.org/description> "Ambroxol is an approved mucolytic which has the potential to combat pulmonary congestion in numerous lung conditions." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692#> <https://schema.org/identifier> "10692" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692#> <https://schema.org/name> "ambroxol" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842#> <https://schema.org/description> "Anti-HIV combination that could be repurposed for COVID-19." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842#> <https://schema.org/identifier> "6842" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842#> <https://schema.org/name> "ribavirin" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624#> <https://schema.org/description> "Opaganib is an orphan drug that is in Phase 2 evaluation. A medRxiv preprint descibes the compassionate use of opaganib in a small cohort of patients with severe COVID-19 (https://www.medrxiv.org/content/10.1101/2020.06.20.20099010v1), predicated upon the drug's anti-inflammatory and anti-viral properties. Results analysis indicated trends in favour of clinical efficacy which led to extended investigation in a Phase 2 randomised placebo-controlled trial in patients with COVID-19 pneumonia." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624#> <https://schema.org/identifier> "6624" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624#> <https://schema.org/name> "opaganib" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733#> <https://schema.org/description> "An in vitro tool compound; inhibitor of serine protease TMPRSS2." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733#> <https://schema.org/identifier> "10733" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733#> <https://schema.org/name> "I-432" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735#> <https://schema.org/description> "Preliminary evidence from a BioRxiv preprint (https://www.biorxiv.org/content/10.1101/2020.03.19.997890v1) indicate that NHC/EIDD-2801 exhibits broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs. The potency of NHC/EIDD-2801 against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735#> <https://schema.org/identifier> "10735" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735#> <https://schema.org/name> "&beta;-D-N<sup>4</sup>-hydroxycytidine" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478#> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <https://schema.org/MolecularEntity> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478#> <http://purl.org/dc/terms/conformsTo> "https://bioschemas.org/profiles/MolecularEntity/0.5-RELEASE" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478#> <https://schema.org/associatedDisease> "COVID-19" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478#> <https://schema.org/description> "Bemcentinib is an investigational, selective and orally active AXL receptor tyrosine kinase inhibitor. Part of its mechanism of action is to inhibit proinflammatory cytokine production. It is being progressed to clinical trial in COVID-19 patients as part of the UK's ACCORD initiative https://bit.ly/2ZXjXOw, to determine if its anti-inflammatory action is efficacious in combating COVID-19 associated hyper-inflammatory response." <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478#> <https://schema.org/identifier> "10478" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478#> <https://schema.org/name> "bemcentinib" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478#> <https://schema.org/url> <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478> <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
<https://www.guidetopharmacology.org/coronavirus.jsp> <http://purl.org/dc/terms/title> "Coronavirus Information | IUPHAR/BPS Guide to PHARMACOLOGY" <https://bioschemas.org/crawl/v1/guidetopharmacology/coronavirus/20200724/0> .
